CN102655859A - 病毒感染的组合疗法治疗 - Google Patents

病毒感染的组合疗法治疗 Download PDF

Info

Publication number
CN102655859A
CN102655859A CN2010800567360A CN201080056736A CN102655859A CN 102655859 A CN102655859 A CN 102655859A CN 2010800567360 A CN2010800567360 A CN 2010800567360A CN 201080056736 A CN201080056736 A CN 201080056736A CN 102655859 A CN102655859 A CN 102655859A
Authority
CN
China
Prior art keywords
hydroxy
antiviral agent
hydroxyl
agent
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800567360A
Other languages
English (en)
Chinese (zh)
Inventor
W.J.吉尔福德
D.H.福尔兹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gemmus Pharma Inc
Original Assignee
Gemmus Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gemmus Pharma Inc filed Critical Gemmus Pharma Inc
Publication of CN102655859A publication Critical patent/CN102655859A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2010800567360A 2009-10-14 2010-10-13 病毒感染的组合疗法治疗 Pending CN102655859A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25156109P 2009-10-14 2009-10-14
US61/251,561 2009-10-14
PCT/US2010/052506 WO2011047048A1 (en) 2009-10-14 2010-10-13 Combination therapy treatment for viral infections

Publications (1)

Publication Number Publication Date
CN102655859A true CN102655859A (zh) 2012-09-05

Family

ID=43063744

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800567360A Pending CN102655859A (zh) 2009-10-14 2010-10-13 病毒感染的组合疗法治疗

Country Status (9)

Country Link
US (2) US20120190637A1 (OSRAM)
EP (1) EP2488168A1 (OSRAM)
JP (1) JP2013508282A (OSRAM)
KR (1) KR20120093955A (OSRAM)
CN (1) CN102655859A (OSRAM)
BR (1) BR112012008959A2 (OSRAM)
CA (1) CA2777384A1 (OSRAM)
NZ (1) NZ599128A (OSRAM)
WO (1) WO2011047048A1 (OSRAM)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105555276A (zh) * 2013-03-15 2016-05-04 格穆斯药业股份有限公司 作为治疗病毒性感染的药剂的贝前列素异构体
CN111184707A (zh) * 2020-02-20 2020-05-22 中山大学 托芬那酸或其药学上可接受的盐在制备预防和/或治疗新型冠状病毒炎症药物中的应用
CN111557939A (zh) * 2020-01-21 2020-08-21 中国人民解放军军事科学院军事医学研究院 法匹拉韦在治疗冠状病毒感染方面的应用
TWI755105B (zh) * 2020-06-11 2022-02-11 長庚大學 抑制冠狀病毒感染與複製的方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5271272B2 (ja) 2006-11-16 2013-08-21 ジェンムス ファーマ インコーポレイティド Ａ型インフルエンザウィルス感染の治療のための薬剤としてのｅｐ２およびｅｐ４作動薬
WO2015109112A1 (en) * 2014-01-16 2015-07-23 Gemmus Pharma Inc. Combination treatment of antibiotic and gpcr agonist for viral/bacterial co-infections
WO2018191475A1 (en) * 2017-04-12 2018-10-18 Vertex Pharmaceuticals Incorporated Combination therapies for treating influenza virus infection
AU2021220877A1 (en) 2020-02-12 2022-09-01 Cytoagents, Inc. Compositions and methods for treating coronavirus infections
WO2021221111A1 (ja) * 2020-04-30 2021-11-04 国立大学法人京都大学 Ｒｎａウイルス関連疾患の予防又は治療剤
MX2022013021A (es) * 2020-04-30 2023-01-16 Minoryx Therapeutics S L Leriglitazona para tratar inflamacion pulmonar y enfermedad pulmonar intersticial.
US20240009214A1 (en) 2020-12-02 2024-01-11 Cipla Limited Method of Treating Viral Infection

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008058766A1 (en) * 2006-11-16 2008-05-22 Bayer Schering Pharma Aktiengesellschaft Ep2 and ep4 agonists as agents for the treatment of influenza a viral infection
EP1975163A1 (en) * 2007-03-28 2008-10-01 Bayer Schering Pharma Aktiengesellschaft Novel 5-cyano-prostacyclin derivatives and their use as agents for the treatment of influenza a viral infection

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2845770A1 (de) 1978-10-19 1980-04-30 Schering Ag Neue prostacyclin-derivate und verfahren zu ihrer herstellung
DE3048906A1 (de) 1980-12-19 1982-07-15 Schering Ag, 1000 Berlin Und 4619 Bergkamen Neue carbacycline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
JPS58124778A (ja) 1982-01-20 1983-07-25 Toray Ind Inc ５，６，７−トリノル−４，８−インタ−ｍ−フエニレンＰＧＩ↓２誘導体
DE3226550A1 (de) 1982-07-13 1984-01-19 Schering AG, 1000 Berlin und 4709 Bergkamen Neue carbacycline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE3306123A1 (de) 1983-02-18 1984-09-06 Schering AG, 1000 Berlin und 4709 Bergkamen Neue carbacycline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE3740838A1 (de) 1987-11-27 1989-06-08 Schering Ag Cyclodextrinclathrate von 5-cyano-prostacyclinderivaten und ihre verwendung als arzneimittel
IL155368A0 (en) 2000-11-27 2003-11-23 Pfizer Prod Inc Ep4 receptor selective agonists in the treatment of osteoporosis
GB0031302D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Napthalene derivatives
GB0031295D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Naphthalene derivatives
US20030027853A1 (en) 2001-06-14 2003-02-06 Allergan Sales, Inc. 3, 7or3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure
US7608637B2 (en) 2001-07-23 2009-10-27 Ono Pharmaceutical Co., Ltd. Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising EP4 agonist as the active ingredient
AU2002346561B2 (en) 2001-12-03 2006-08-17 Merck & Co., Inc. EP4 receptor agonist, compositions and methods thereof
JP2005514378A (ja) 2001-12-03 2005-05-19 メルク　エンド　カムパニー　インコーポレーテッド 高眼圧症の治療方法
MXPA04009243A (es) 2002-04-12 2005-06-08 Pfizer Uso de ligandos para el receptor ep4 en el tratamiento de enfermedades vinculadas a il-6.
AU2003233731A1 (en) 2002-06-06 2003-12-22 Xavier Billot 1,5-disubstituted imidazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of eye and bone diseases
WO2003103772A1 (en) 2002-06-06 2003-12-18 Merck Frosst Canada & Co. 1,5-distributed pyrrolid-2-one derivatives for use as ep4 receptor agonists in the teatment of eye diseases such as glaucoma
WO2004019938A1 (en) 2002-08-28 2004-03-11 Merck Frosst Canada & Co. Oxazolidin-2-one and thiazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of glaucoma
WO2004037786A2 (en) 2002-10-25 2004-05-06 Merck Frosst Canada & Co. 2-pyrrolidones as ep4 receptor agonists
US7053085B2 (en) 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof
JP4582456B2 (ja) 2003-01-21 2010-11-17 小野薬品工業株式会社 ８−アザプロスタグランジン誘導体およびその医薬用途
AU2004211936B2 (en) 2003-02-11 2008-09-11 Allergan, Inc. 10,10-dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure
GB0306907D0 (en) 2003-03-26 2003-04-30 Angiogene Pharm Ltd Boireductively-activated prodrugs
US6747037B1 (en) 2003-06-06 2004-06-08 Allergan, Inc. Piperidinyl prostaglandin E analogs
US7326716B2 (en) 2003-06-06 2008-02-05 Allergan, Inc. Treatment of inflammatory bowel disease
US7015243B2 (en) 2003-08-28 2006-03-21 Allergan, Inc. Cyclohexyl prostaglandin analogs as EP4-receptor agonists
WO2005027931A1 (en) 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an ep2 or ep4 selective agonist
US20070191319A1 (en) 2003-12-17 2007-08-16 Pfizer Inc. Treatment of conditions that present with low bone mass by continuous combination therapy with selective prostaglandin ep4 receptor agonists and an estrogen
US7169807B2 (en) 2004-04-09 2007-01-30 Allergan, Inc. 10-Hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists
WO2005116010A1 (en) 2004-05-26 2005-12-08 Merck Frosst Canada Ltd. Ep4 receptor agonist, compositions and methods thereof
WO2006016695A1 (ja) 2004-08-10 2006-02-16 Ono Pharmaceutical Co., Ltd. Ｅｐ４アゴニストを含有してなる高カリウム血症の予防および／または治療剤
WO2006047476A2 (en) 2004-10-26 2006-05-04 Allergan, Inc. Therapeutic and delivery methods of prostaglandin ep4 agonists
US7994195B2 (en) 2004-11-04 2011-08-09 Allergan, Inc. Therapeutic substituted piperidone compounds
US7101906B2 (en) 2004-11-16 2006-09-05 Allergan, Inc. 2,3,4-substituted cyclopentanones as therapeutic agents
US7183324B2 (en) 2004-11-23 2007-02-27 Allergan, Inc. 2,3,4-substituted cyclopentanones as therapeutic agents
CN101133037B (zh) 2005-01-27 2012-05-09 旭化成制药株式会社 六元杂环化合物及其用途
WO2006137472A1 (ja) 2005-06-24 2006-12-28 Taisho Pharmaceutical Co., Ltd. プロスタグランジン誘導体
JP2009502977A (ja) 2005-08-03 2009-01-29 メルク フロスト カナダ リミテツド Ｅｐ４受容体アゴニスト、この組成物および方法
JP2009502982A (ja) 2005-08-03 2009-01-29 メルク フロスト カナダ リミテツド Ｅｐ４受容体アゴニスト、この組成物および方法
US7893107B2 (en) 2005-11-30 2011-02-22 Allergan, Inc. Therapeutic methods using prostaglandin EP4 agonist components
GB0602900D0 (en) 2006-02-13 2006-03-22 Glaxo Group Ltd Novel Compounds
WO2007139150A1 (ja) * 2006-05-30 2007-12-06 The University Of Tokushima ＴＮＦα阻害物質を含有してなる抗インフルエンザウイルス剤
EP2035376B1 (en) 2006-06-12 2014-08-27 Merck Canada Inc. Indoline amide derivatives as ep4 receptor ligands
GB0615111D0 (en) 2006-07-28 2006-09-06 Glaxo Group Ltd Novel compounds
GB0615105D0 (en) 2006-07-28 2006-09-06 Glaxo Group Ltd Novel compounds
EP2054401B1 (en) 2006-08-11 2013-05-01 Merck Canada Inc. Thiophenecarboxamide derivatives as ep4 receptor ligands
GB0620619D0 (en) 2006-10-17 2006-11-29 Glaxo Group Ltd Novel compounds
GB0623203D0 (en) 2006-11-21 2007-01-03 Glaxo Group Ltd Novel compounds
JP5069752B2 (ja) 2006-12-15 2012-11-07 グラクソ グループ リミテッド Ｅｐ４受容体アゴニストとしてのベンズアミド誘導体
US7776896B2 (en) 2007-03-28 2010-08-17 Bayer Schering Pharma Aktiengesellschaft 5-cyano-prostacyclin derivatives as agents for the treatment of influenza a viral infection
EP2147672A4 (en) 2007-05-08 2011-11-02 Nat University Corp Hamamatsu University School Of Medicine CYTOTOXIC T CELL ACTIVATOR WITH AN EP4 AGONIST

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008058766A1 (en) * 2006-11-16 2008-05-22 Bayer Schering Pharma Aktiengesellschaft Ep2 and ep4 agonists as agents for the treatment of influenza a viral infection
EP1975163A1 (en) * 2007-03-28 2008-10-01 Bayer Schering Pharma Aktiengesellschaft Novel 5-cyano-prostacyclin derivatives and their use as agents for the treatment of influenza a viral infection

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105555276A (zh) * 2013-03-15 2016-05-04 格穆斯药业股份有限公司 作为治疗病毒性感染的药剂的贝前列素异构体
CN111557939A (zh) * 2020-01-21 2020-08-21 中国人民解放军军事科学院军事医学研究院 法匹拉韦在治疗冠状病毒感染方面的应用
CN111557939B (zh) * 2020-01-21 2021-05-04 中国人民解放军军事科学院军事医学研究院 法匹拉韦在制备用于治疗冠状病毒感染的药物中的应用
WO2021147235A1 (zh) * 2020-01-21 2021-07-29 中国人民解放军军事科学院军事医学研究院 法匹拉韦在治疗冠状病毒感染方面的应用
US11318135B2 (en) 2020-01-21 2022-05-03 Academy Of Military Medical Sciences Use of Favipiravir in treatment of coronavirus infection
CN111184707A (zh) * 2020-02-20 2020-05-22 中山大学 托芬那酸或其药学上可接受的盐在制备预防和/或治疗新型冠状病毒炎症药物中的应用
TWI755105B (zh) * 2020-06-11 2022-02-11 長庚大學 抑制冠狀病毒感染與複製的方法

Also Published As

Publication number Publication date
AU2010306914A1 (en) 2012-04-19
JP2013508282A (ja) 2013-03-07
KR20120093955A (ko) 2012-08-23
US20150196578A1 (en) 2015-07-16
WO2011047048A1 (en) 2011-04-21
US20120190637A1 (en) 2012-07-26
BR112012008959A2 (pt) 2019-09-24
CA2777384A1 (en) 2011-04-21
NZ599128A (en) 2014-02-28
EP2488168A1 (en) 2012-08-22

Similar Documents

Publication Publication Date Title
CN102655859A (zh) 病毒感染的组合疗法治疗
JP7366385B2 (ja) ヘルペスウイルス誘発疾患の処置のための方法および組成物
US11072648B2 (en) Mast cell stabilizers for treatment of fever
JP2016512833A (ja) ウイルス感染症の治療薬としてのベラプロスト異性体
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
KR20240119346A (ko) 코로나바이러스의 치료 방법
AU2016287580A2 (en) Compositions and methods for the treatment of viral infection
CN101939001B (zh) 用于治疗卵巢癌的含有紫杉醇的组合
CA2465062C (en) Preventive and/or therapeutic agent for viral infection
RU2011105463A (ru) ФАРМАЦЕВТИЧЕСКИЙ ПРОДУКТ, СОДЕРЖАЩИЙ АНТАГОНИСТ МУСКАРИНОВОГО РЕЦЕПТОРА И АГОНИСТ β2-АДРЕНОРЕЦЕПТОРА
JP2019085364A5 (OSRAM)
CN108472375A (zh) 中重度流感的治疗方法
AU2010306914B2 (en) Combination therapy treatment for viral infections
JP2013542262A5 (OSRAM)
JP2025512970A (ja) インフルエンザ及びポックスウイルス科ウイルス感染症の治療方法
WO2022145407A1 (ja) Ｄｐ１アンタゴニストおよびノイラミニダーゼ阻害剤からなるウイルス性気道感染症治療用医薬
EA048350B1 (ru) Применение даларгина для профилактики орви и предотвращения развития осложнений при заболеваниях орви
JP2019524860A5 (OSRAM)
HK40011695A (en) Norketotifen for treatment of hypercytokinemia and viral infections
HK40011695B (en) Norketotifen for treatment of hypercytokinemia and viral infections

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20120905

RJ01 Rejection of invention patent application after publication